К содержанию
Dr. Tara EinullaevaMedical oncologist

Cancer glossary

Metabolic response on PET-CT: complete, partial and PERCIST criteria

Metabolic response is the change in tumor FDG uptake on PET-CT after therapy. What complete and partial response mean, PERCIST cut-offs and why timing matters.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026

In short

Metabolic response is the change in tumor activity on PET-CT compared with the scan before treatment: how much less FDG the lesions take up. It adds to the size-based assessment (RECIST) rather than replacing it.

How it appears in your report

  • “Complete metabolic response (CMR)” — no active tissue visible.
  • “Partial metabolic response (PMR): SULpeak down by …%”.
  • “Stable metabolic disease (SMD)”.
  • “Progressive metabolic disease (PMD)”, “new hypermetabolic lesions”.
  • “Residual metabolic activity in …” — part of a lesion still takes up FDG.

What it means

The criteria used most often are PERCIST 1.0 (2009). They are based on SULpeak, the uptake in the most active part of a lesion adjusted for lean body mass.

Category PERCIST criterion
Complete metabolic response Uptake in the lesion below the liver average and at blood pool background, no new active lesions
Partial metabolic response SULpeak down by at least 30% and at least 0.8 units, no new lesions
Stable metabolic disease Neither response nor progression
Progressive metabolic disease SULpeak up by more than 30% and by 0.8 units, a clear increase in the extent of uptake, or new lesions typical of cancer

There are also older EORTC criteria (1999), which are likewise based on percentage change in SUV. The report usually states which system was used. A single SUVmax value without a comparison does not define a response.

Does it affect treatment

Metabolic response is weighed together with lesion size, examination and blood tests. A common trap is timing: inflammation after radiotherapy or surgery takes up FDG and can mimic tumor, while a scan done too soon after radiotherapy can sometimes underestimate activity. So when to do PET-CT and how to read it is decided by your treating doctor. If you have a PET-CT and a CT with different conclusions, I can go through them in a consultation.

Questions to ask your doctor

  • Which criteria were used to assess response, and which scan was this compared with?
  • Was the scan done too soon after treatment?
  • If PET-CT and CT disagree, which one will we rely on?

Sources

  1. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors — Wahl R.L. et al., Journal of Nuclear Medicine, 2009
  2. PET Response Criteria in Solid Tumors (PERCIST) — Radiopaedia
  3. The role of 18F-FDG PET/CT in monitoring tumour response — HealthManagement (Imaging Management), 2010

Watch me explain this on video

Short videos on my Instagram (in Russian)

FAQ

Related terms

This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.

Related articles

All blog articles